

Keith C Bible

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8637515/publications.pdf>

Version: 2024-02-01

55
papers

14,004
citations

185998

28
h-index

214527

47
g-index

55
all docs

55
docs citations

55
times ranked

10834
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	2.4	10,674
2	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	2.4	717
3	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. <i>Lancet Oncology</i> , The, 2010, 11, 962-972.	5.1	390
4	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 337-386.	2.4	297
5	A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3179-3184.	1.8	148
6	Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy. <i>Thyroid</i> , 2011, 21, 25-30.	2.4	139
7	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26.	2.4	122
8	A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1687-1693.	1.8	117
9	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 830-842.	5.5	106
10	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	0.8	100
11	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1943-1950.	1.8	86
12	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4506-4514.	1.8	86
13	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 403-416.	12.5	80
14	Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points. <i>Clinical Cancer Research</i> , 2005, 11, 5935-5941.	3.2	65
15	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	0.8	64
16	Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 138-148.	1.9	59
17	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020, 21, 100282.	1.0	59
18	Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer. <i>Science Translational Medicine</i> , 2013, 5, 166ra3.	5.8	58

#	ARTICLE	IF	CITATIONS
19	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 469-481.	5.5	58
20	Diagnosis and Management of Anaplastic Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 269-284.	1.2	58
21	A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261. <i>Gynecologic Oncology</i> , 2012, 127, 55-62.	0.6	52
22	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2019, 29, 1615-1622.	2.4	51
23	External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. <i>Advances in Radiation Oncology</i> , 2018, 3, 25-29.	0.6	47
24	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	0.9	41
25	Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2017, 57, 220-225.	1.1	40
26	Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1357-1375.	1.9	39
27	Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. <i>Annals of Surgical Oncology</i> , 2017, 24, 1546-1550.	0.7	38
28	Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 923-927.	2.4	31
29	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
30	New drugs for medullary thyroid cancer: new promises?. <i>Endocrine-Related Cancer</i> , 2016, 23, R287-R297.	1.6	20
31	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 1254-1262.	2.4	19
32	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa069.	0.1	14
33	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4387-4395.	1.8	12
34	Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers. <i>Journal of Oncology Practice</i> , 2012, 8, e1s-e5s.	2.5	11
35	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2346-e2357.	1.8	11
36	Development and Characterization of a Differentiated Thyroid Cancer Cell Line Resistant to VEGFR-Targeted Kinase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E936-E943.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. <i>Thyroid</i> , 2021, 31, 332-333.	2.4	8
38	Treating advanced radioresistant differentiated thyroid cancer. <i>Lancet Oncology</i> , The, 2012, 13, 854-855.	5.1	7
39	Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 145-151.	0.4	7
40	Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 285-289.	0.4	7
41	Mutated BRAF and personalised medicine in differentiated thyroid cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1181-1183.	5.1	5
42	Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac044.	0.1	5
43	Individualization of Therapies for Patients with Advanced Differentiated Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3092-3093.	1.8	3
44	“Pseudo-progression” in advanced thyroid cancer in response to kinase inhibitor therapy. <i>Endocrine</i> , 2017, 57, 187-188.	1.1	3
45	Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. <i>Endocrine</i> , 2018, 59, 228-229.	1.1	3
46	Toward improved outcomes in patients with anaplastic thyroid cancer. <i>Oncology</i> , 2012, 26, 398, 401, 406.	0.4	3
47	Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. <i>AACE Clinical Case Reports</i> , 2021, 7, 334-335.	0.4	2
48	Systemic Therapeutic Approaches to Advanced Thyroid Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 389-392.	1.8	2
49	Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 521-522.	2.5	0
50	Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer. <i>Endocrine</i> , 0, , .	1.1	0
51	Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer. <i>Endocrine</i> , 2017, 57, 364-365.	1.1	0
52	Anaplastic Thyroid Carcinoma. , 2019, , 693-700.		0
53	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma. , 2021, , 246-254.e3.		0
54	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. <i>Blood</i> , 2004, 104, 3461-3461.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. American Journal of Managed Care, 2012, 18, e162-7.	0.8	0